NCT05696522 Stereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 6 participants in total. It began in 2023-01-12 with a primary completion date of 2026-05-02.

Brief Summary

Ventricular tachycardia (VT) is an abnormal rhythm arising from the bottom chambers (ventricles) of the heart. The hearts of most patients who develop VT have been previously damaged by a myocardial infarction (heart attack) or other heart muscle diseases (cardiomyopathies). The damage produces scar or fatty deposits that conduct electrical impulses slowly allowing VT to occur. Recurrent episodes of VT can compromise heart function and increase mortality. VT is prevented by special drugs but these are not always effective and can have many side effects. Most patients with VT will also have a specialised device called an implantable defibrillator (ICD) implanted. The ICD treats VT by either stimulating the heart rapidly or delivering a shock to it. ICDs are very effective but the shocks are painful and have a big impact on quality of life. If VT occurs despite optimal drug treatment, patients undergo an invasive procedure called catheter ablation. Here, wires are passed into the heart from the blood vessels in the leg and the damaged heart muscle causing the VT is identified whilst the heart is in VT. An electrical current is passed down the wire making its tip heat up allowing discrete burns (ablation) to be placed inside the heart. The ablated heart muscle doesn't conduct electricity which stops the VT and prevents it recurring. Some patients are so frail that ablation cannot be performed safely. A recent clinical trial has shown that VT can be treated in such patients using radiotherapy, which is usually used to treat tumours with high energy radiation. This approach is non-invasive, painless and requires no sedation or anaesthesia. This study will test whether VT can be successfully treated using stereotactic ablative radiotherapy. This can deliver high dose radiotherapy very precisely, whilst minimising the risk of damage to healthy tissues.

Eligibility Criteria

Inclusion Criteria: 1. They are at least 18-85 years old. 2. They have recurrent VT (at least three episodes in the preceding six months) requiring therapy from an ICD, that is refractory to conventional treatments - both maximally tolerated doses of anti- arrhythmic drugs and/or conventional catheter ablation. 3. They are too frail or do not wish to undergo conventional catheter ablation. 4. They have not had previous radiotherapy to the anticipated treatment field. Exclusion Criteria: 1. They have polymorphic VT or ventricular fibrillation (VF). 2. They have inotrope-dependent heart failure or a left ventricular assist device (LVAD) in situ. 3. They are unlikely to live more than 12 months irrespective of the VT. 4. There is a potentially reversible cause for the VT e.g. critical coronary artery disease or a metabolic problem such as an overactive thyroid gland. 5. They are unable to provide informed consent. 6. They have had previous radiotherapy to the anticipated treatment field. 7. The patient weighs in excess of 170kg (maximum weight capacity of the tables in the imaging department).

Contact & Investigator

Frequently Asked Questions

Related Trials